Drug Search Results
More Filters [+]


Alternative Names: trandolapril, mavik, tarka
Latest Update: 2024-04-04
Latest Update Note: News Article

Product Description

Trandolapril is an angiotensin converting enzyme (ACE) inhibitor. It works by blocking a substance in the body that causes the blood vessels to tighten. As a result, trandolapril relaxes the blood vessels. This lowers blood pressure and increases the supply of blood and oxygen to the heart. (Sourced from: https://www.mayoclinic.org/drugs-supplements/trandolapril-oral-route/side-effects/drg-20069242?p=1)

Mechanisms of Action: ACE Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Bangladesh | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hungary | India | Indonesia | Ireland | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trandolapril

Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: COVID-19|Influenza, Human|Pneumonia



Trial Status


Primary Completion Date

Probability of Success




Pneumonia|COVID-19|Influenza, Human


Recent News Events